208 related articles for article (PubMed ID: 16127288)
21. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
Bonnesen B; Pappot H; Holmstav J; Skov BG
Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of surgical-pathologic N1 lymph node involvement in non-small cell lung cancer.
Demir A; Turna A; Kocaturk C; Gunluoglu MZ; Aydogmus U; Urer N; Bedirhan MA; Gurses A; Dincer SI
Ann Thorac Surg; 2009 Apr; 87(4):1014-22. PubMed ID: 19324121
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients.
Kato T; Daigo Y; Aragaki M; Ishikawa K; Sato M; Kondo S; Kaji M
Lung Cancer; 2011 Oct; 74(1):124-31. PubMed ID: 21376419
[TBL] [Abstract][Full Text] [Related]
26. Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer.
Moisa A; Fritz P; Eck A; Wehner HD; Mürdter T; Simon W; Gabius HJ
Anticancer Res; 2007; 27(4B):2131-9. PubMed ID: 17695496
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer.
Sakao Y; Miyamoto H; Yamazaki A; Oh T; Fukai R; Shiomi K; Saito Y
Ann Thorac Surg; 2006 Jan; 81(1):292-7. PubMed ID: 16368383
[TBL] [Abstract][Full Text] [Related]
28. Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer.
Yamauchi A; Kontani K; Kihara M; Nishi N; Yokomise H; Hirashima M
Breast J; 2006; 12(5 Suppl 2):S196-200. PubMed ID: 16959001
[TBL] [Abstract][Full Text] [Related]
29. Combined analysis of tumor growth pattern and expression of endogenous lectins as a prognostic tool in primary testicular cancer and its lung metastases.
Kayser K; Hoeft D; Hufnagi P; Caselitz J; Zick Y; André S; Kaltner H; Gabius HJ
Histol Histopathol; 2003 Jul; 18(3):771-9. PubMed ID: 12792889
[TBL] [Abstract][Full Text] [Related]
30. Galectin-3 - an emerging prognostic indicator in advanced head and neck carcinoma.
Plzák J; Betka J; Smetana K; Chovanec M; Kaltner H; André S; Kodet R; Gabius HJ
Eur J Cancer; 2004 Oct; 40(15):2324-30. PubMed ID: 15454259
[TBL] [Abstract][Full Text] [Related]
31. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
[TBL] [Abstract][Full Text] [Related]
32. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
33. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer.
Sienel W; Dango S; Woelfle U; Morresi-Hauf A; Wagener C; Brümmer J; Mutschler W; Passlick B; Pantel K
Clin Cancer Res; 2003 Jun; 9(6):2260-6. PubMed ID: 12796394
[TBL] [Abstract][Full Text] [Related]
34. [Retinoid expression (RARbeta and CRBP1) in non-small-cell lung carcinoma].
Mauro LV; Dalurzo M; Smith D; Lastiri J; Vasallo B; Joffei EB; Pallotta MG; Puricelli L
Medicina (B Aires); 2008; 68(3):205-12. PubMed ID: 18689151
[TBL] [Abstract][Full Text] [Related]
35. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
[TBL] [Abstract][Full Text] [Related]
36. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer.
Harpole DH; Richards WG; Herndon JE; Sugarbaker DJ
Ann Thorac Surg; 1996 May; 61(5):1470-6. PubMed ID: 8633961
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor expression in pN2 non-small cell lung cancer: lack of prognostic value.
Tomita M; Matsuzaki Y; Shimizu T; Hara M; Ayabe T; Onitsuka T
Respirology; 2005 Jan; 10(1):31-5. PubMed ID: 15691235
[TBL] [Abstract][Full Text] [Related]
38. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
39. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer.
Iwata T; Uramoto H; Sugio K; Fujino Y; Oyama T; Nakata S; Ono K; Morita M; Yasumoto K
Lung Cancer; 2005 Oct; 50(1):67-73. PubMed ID: 15950316
[TBL] [Abstract][Full Text] [Related]
40. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
